The UK’s National Institute for Health and Care Excellence has authorized the use of pembrolizumab in combination with carboplatin and either paclitaxel or nab-paclitaxel for the treatment of patients with metastatic squamous non–small cell lung cancer.
Original Article: NICE Approves Frontline Pembrolizumab Regimen for Squamous NSCLC